A rapid HPLC bio-analytical method has been developed and validated for the simultaneous quantification of Ombitasvir (OMBTSR), Ritonavir (RTNVR), Paritaprevir (PTVR) in human plasma. OMBTSR and PTVR are used to control Hepatitis-C infection. RTNVR is used in the treatment of HIV/AIDS. The method was developed with Column (Intersil ODSC 18, 250 mm × 4.6 mm × 5µ) at 230 nm wave length and at flow rate of 1.0 mL/min. The mobile phase consisted of 20% Acetonitrile, 20% Methanol, 60% 1mM NH 4 H 2 PO 4 Buffer(P H 6.5 v/v). The retention times of RTNVR, OMBTSR, PTVR are 5.7 min. 7.8 min. and 12.8 min. respectively. The method was developed and validated in terms of linearity, interday precision, intraday precision, accuracy, LOQ, LOD and stability study. The proposed method is useful in pharmacokinetic studies using HPLC or LC-MS.
INTRODUCTION
Ritonavir (RTNVR) is an antiretroviral drug used along with other medications to treat HIV/AIDS and hepatitis C. [1] [2] [3] . Ombitasvir (OMBTSR) is an antiviral drug for the treatment of hepatitis C virus. Mostly it is used in the combinations with in combination with Paritaprevir, Ritonavir and Dasabuvir 4 . Paritaprevir (PTVR) is best drug in the treatment of hepatitis C. The usual side effects of this combination are Diarrhea, Vomiting, loss of appetite and numbness of the hands and feet. The serious side effects are liver problems, pancreatitis, allergic reactions, and Arrhythmias 5 . From last few decades, Pharmacokinetics playing major important role in drug development. At the time of identification of drug's biological properties, metabolic feature of the drug and understanding of pharmacokinetic the bioanalytical methods playing key role. The bioanalytical method used to determine the drug and its metabolites in serum, plasma, urine [6] [7] [8] [9] [10] [11] [12] . 3 OH in the ratio of 50:35:15v/v at pH 6.0 linear in the ranges are 400-600µg/ml for Lopinavir and 100-150 µg/ml for RTNVR.
Objective
The present study is concerned with the development and validation of RTNVR, OMBTSR and PTVR in spiked human plasma by HPLC.
MATERIALS AND METHODS

Apparatus
The new method was developed and validated with Peak LC P7000 HPLC (Isocratic) system rheodyne injector with 20 µL and UV/Vis detector UV7000 and PEAK Chromatographic version 1.06. The Ombitasvir, Ritonavir Paritaprevir were scanned with UV-Visible spectrophotometer (Tech comp-UV 2301, make Japan) with Hitachi software. OMBTSR, RTNVR and PTVR were obtained from Manus Aktteva Biopharma LLP (India). HPLC grade solvents Water, Acetonitrile, Methanol and Tri Ethyl Amine (TEA) were procured from Merck, Mumbai. Method was developed at 230 nm with Intersil ODS C18 column (250 mm × 4.6 mm×5µ).
Chromatographic conditions
The HPLC method conditions were optimized by using different columns, different mobile phases and different buffers. The finalized mobile phase is 20% Acetonitrile, 20% Methanol, 60% 0.001 M NH 4 H 2 PO 4 Buffer v/v. The mobile phase P H was adjusted to 6.5 with TEA for perfect separation. Analysis was performed with flow rate 1.0 ml/min. at ambient temperature.
Standard stock solution preparation 19 The plasma samples was extracted by liquid-liquid extraction process. The fixed dosages (10mg) are spiked in to 10ml plasma and stored in freezer for 24 hours. For processing, the stored spiked samples were taken out from freezer and allowed to thaw at room temperature. An aliquot of 500µL was transferred to prelabeled 10.0ml polypropylene centrifuge tubes. Extraction solvent, 5.0ml of ethyl acetate, was then added to extract the drug. The samples were then kept on a vibramax unit and vortexed for 15 minute. Samples were centrifuged at 5000 rpm for 5 min. in a refrigerated centrifuge (4°C). Supernatant solution, 1 ml was then transferred into pre-labeled polypropylene tubes and was allowed to evaporate to dryness under N 2 at 40°C. The dried residue dissolved in 200µL of mobile phase and transferred into shell vials containing vial inserts for analysis. Samples, 20µL by volume, were then injected into the column and analyzed by HPLC on the same day to avoid any degradation. The column temperature was maintained at ambient temperature.
Validation Linearity Test
The Linearity test was conducted in the range of 25% to 200%. For RTNVR and PTVR the concentrations ranges are 0.15 to 1.2µg/ml. For OMBTR the linearity range is 0.25 µg/ml to 2.0 µg/ ml . The results are showed in below Table. 1. The target concentration solutions are prepared by 
Precision
Intraday precision and Interday precision tests were conducted at standard concentrations of RTNVR, OMBTSR and PTVR i.e 0.6 µg/ml, 1.0µg/ ml and 0.6µg/ml respectively. The Precision was expressed as the percentage of RSD(Relative Standard Deviation). The calculated percentage RSD of intraday and inter day precision test of each drug is below 2.0.
Recovery
The recovery test was conducted at three different concertinos levels 50%, 100% and 150%. Recovery of RTNVR, OMBTSR and PTVR was evaluated by comparing of observed peak area with Table. 2.
Sensitivity
The sensitivity of method was calculated by signal to noise ratio. The plasma sample solution was diluted serially and injected at developed conditions. Similarly, blank plasma samples were also processed and injected. The results were showed in Table. 3.
Stability
The stability experiments were aimed at testing all possible conditions that the samples might experience after collecting and prior the analysis. Short term BT (Bench-Top) stability test was evaluated after 24 h. at room temperature. Autosampler stability test was evaluated on QCs extracts maintained in the auto sampler at 10 o C for 24 h, by comparing their concentrations with freshextracts. Freeze and Thaw stability test evaluated after three cycles at -20 0 C to room temperature, by comparison with freshly prepared.Stability of RTNVR, OMBTSR and PTVR solutions was observed at room and temperature and in refrigerated conditions for period of 48 hours. Acceptable stability has been considered as percent difference in concentration lower than 5%. The stability study results were showed in Table. 4. 
RESULTS AND DISCUSSION
The developed method was simple, accurate and precise than reported methods. In this method the primarily chromatographic experiments were set to elute selected analytes in biological fluid. The method was validated over the concentration range of 0.15-1.2 µg/ml for RTNVR, PTVR and 0.25-2.0 µg/ml for OMBTSR. The mean percent recovery of RTNVR is 99.81%, OMBTSR is 101.42% and PTVR is 100.38. The intraday and inter day precision were conducted at standard concentration limits, the Percentage of RSD is below 2%. The LOQ concentrations are 0.0375 µg/ml for RTNVR, PTVR and 0.0625 µg/ml for OMBTSR. Stability (Bench top, Auto sampler, Freeze thaw) of compounds was established in a series of stability studies.
CONCLUSION
This method is suitable use in clinical studies to determination optimal therapeutic ranges for RTNVR, OMBTSR and PTVR and then for regular analysis and the rapeutically drug monitoring of RTNVR, OMBTSR and PTVR.
